^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HRS-4642

    i
    Other names: HRS-4642, HRS 4642, HRS4642, SHR-4642
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    KRAS G12D inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Zhejiang University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    paclitaxel • TheraCIM (nimotuzumab) • HRS-4642
    17d
    HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P3, N=588, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    HRS-4642
    18d
    HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, West China Hospital | N=10 --> 20
    Enrollment change
    |
    TheraCIM (nimotuzumab) • HRS-4642
    2ms
    HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients (clinicaltrials.gov)
    P2, N=32, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • HRS-4642
    2ms
    A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=118, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRS-4642
    3ms
    A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Enrolling by invitation --> Active, not recruiting | N=70 --> 47
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed • AiRuiLi (adebrelimab) • HRS-4642
    3ms
    Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov)
    P1, N=102, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    HRS-4642
    3ms
    HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | N=60 --> 30
    Enrollment change
    |
    gemcitabine • albumin-bound paclitaxel • HRS-4642
    4ms
    HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    5ms
    HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective phase Ib/II trial. (PubMed, Front Pharmacol)
    This study was registered on ClinicalTrials.gov with NCT06773130. This study protocol has been approved by the Ethics Committee of West China Hospital [2024 (2239)].
    P1/2 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D
    |
    TheraCIM (nimotuzumab) • HRS-4642
    5ms
    HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Ruijin Hospital | N=20 --> 60 | Not yet recruiting --> Recruiting
    Enrollment open • Enrollment change
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    7ms
    Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=32, Not yet recruiting, Henan Cancer Hospital
    New P1/2 trial
    |
    SHR-A2102 • HRS-4642